<DOC>
	<DOCNO>NCT02944201</DOCNO>
	<brief_summary>This single arm , window opportunity study men treatment-naïve prostate cancer proceed prostatectomy . Men treat carvedilol prior undergoing prostatectomy .</brief_summary>
	<brief_title>Beta Adrenergic Receptor Blockade Novel Therapy Patients With Adenocarcinoma Prostate</brief_title>
	<detailed_description>Preclinical research demonstrate autonomic nerve fiber prostate gland regulate prostate cancer development dissemination . Studies human prostate cancer specimens indicate high density autonomic nerve fiber associate poor clinical outcome . In clinical trial beta-blocker carvedilol give men diagnose prostate cancer . Men begin carvedilol follow diagnostic prostate biopsy continue carvedilol prostatectomy . The primary outcome measure change Ki-67 TUNEL assay biomarkers prostate biopsy prostatectomy tissue .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<criteria>1 . The patient must able provide studyspecific inform consent prior study entry . 2 . Age ≥ 18 3 . ECOG Performance Status 01 4 . Pathologically proven diagnosis prostate adenocarcinoma diagnose prostate biopsy archival biopsy tissue available analysis . The amount cancer tissue present must sufficient analysis . 5 . Prostate adenocarcinoma classify intermediate highrisk define one follow criterion : PSA &gt; 10 ng/ml , Gleason score ≥7 , tumor stage ≥T2b 6 . Patients must evidence metastatic disease ( include clinically negative pelvic lymph node ) establish image ( CT MRI pelvis bone scan ) within 60 day prior registration . Equivocal bone scan finding allow plain film xrays negative metastasis . 7 . The patient attend urologist decide proceed prostatectomy 8 . Lab value meet follow criterion 1 . Total bilirubin &lt; 2.0 X Upper Limit Normal ( ULN ) 2 . Aspartate aminotransferase ( AST ) ≤ 2.5 X ULN . 3 . Alanine aminotransferase ( ALT ) ≤ 2.5 X ULN 4 . Absolute Neutrophil Count ( ANC ) &gt; 1.5 K/mm3 5 . Platelets &gt; 100 K/mm3 6 . Hemoglobin ≥9.0 g/dL 7. calculated creatinine clearance ≥ 40 mL/min 9 . Patients low risk prostate adenocarcinoma define meet three follow criterion : Gleason score ≤6 , PSA &lt; 10 tumor stage ≤T2b 10 . The presence metastatic disease include pelvic lymph node 11 . Use betablocker time diagnostic biopsy prostate cancer use betablocker time screen . If investigator believe carvedilol safely add patient exist antihypertensive regimen , patient eligible study . 12 . Prior therapy prostate cancer include radiation therapy ( external beam brachytherapy ) , surgery , highintensity focus ultrasound ( HIFU ) , cryotherapy , previous hormonal therapy androgen deprivation therapy bilateral orchiectomy LHRH analogue ( e.g . leuprolide , goserelin , triptorelin , degarelix ) , antiandrogens , ketoconazole , abiraterone chemotherapy ( prostate cancer , chemotherapy past indication allow ) . 13 . Treatment investigational agent within 30 day prior register protocol therapy . 14 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least 5 year . 15 . Inability take oral medication 16 . Hypotension ( systolic blood pressure &lt; 100 mm Hg diastolic blood pressure &lt; 50 mm Hg ) bradycardia ( pulse &lt; 55 beats/min ) screening . For patient function pacemaker , bradycardia exclusion . 17 . Bronchial asthma relate bronchospastic condition chronic obstructive pulmonary disease . 18 . Patients must New York Heart Association Class III IV heart failure time screening . Patients must unstable angina , myocardial infarction , serious uncontrolled cardiac arrhythmia within 6 month prior registration . 19 . Prolonged QTc interval preentry 12lead ECG ( &gt; 460 msec ) , obtain within 28 day prior register study . No second thirddegree atrioventricular block screen 12lead ECG . 20 . Any serious illness medical condition principal investigator feel would make patient poor candidate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>carvedilol</keyword>
	<keyword>biomarkers</keyword>
	<keyword>autonomic nerve</keyword>
</DOC>